Insulin Pump Therapy Is Associated with Lower Rates of Retinopathy and Peripheral Nerve Abnormality

Bedowra Zabeen, Maria E Craig, Sohaib A Virk, Alison Pryke, Albert K F Chan, Yoon Hi Cho, Paul Z Benitez-Aguirre, Stephen Hing, Kim C Donaghue, Bedowra Zabeen, Maria E Craig, Sohaib A Virk, Alison Pryke, Albert K F Chan, Yoon Hi Cho, Paul Z Benitez-Aguirre, Stephen Hing, Kim C Donaghue

Abstract

Objective: To compare rates of microvascular complications in adolescents with type 1 diabetes treated with continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI).

Research design and methods: Prospective cohort of 989 patients (aged 12-20 years; diabetes duration >5 years) treated with CSII or MDI for >12 months. Microvascular complications were assessed from 2000-14: early retinopathy (seven-field fundal photography), peripheral nerve function (thermal and vibration threshold testing), autonomic nerve abnormality (heart rate variability analysis of electrocardiogram recordings) and albuminuria (albumin creatinine ratio/timed overnight albumin excretion). Generalized estimating equations (GEE) were used to examine the relationship between treatment and complications rates, adjusting for socio-economic status (SES) and known risk factors including HbA1c and diabetes duration.

Results: Comparing CSII with MDI: HbA1C was 8.6% [70mmol/mol] vs. 8.7% [72 mmol/mol]) (p = 0.7), retinopathy 17% vs. 22% (p = 0.06); microalbuminuria 1% vs. 4% (p = 0.07), peripheral nerve abnormality 27% vs. 33% (p = 0.108) and autonomic nerve abnormality 24% vs. 28% (p = 0.401). In multivariable GEE, CSII use was associated with lower rates of retinopathy (OR 0.66, 95% CI 0.45-0.95, p = 0.029) and peripheral nerve abnormality (OR 0.63, 95% CI 0.42-0.95, p = 0.026), but not albuminuria (OR 0.46, 95% CI 0.10-2.17, p = 0.33). SES was not associated with any of the complication outcomes.

Conclusions: In adolescents, CSII use is associated with lower rates of retinopathy and peripheral nerve abnormality, suggesting an apparent benefit of CSII over MDI independent of glycemic control or SES.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Rate of microvascular complications according…
Fig 1. Rate of microvascular complications according to insulin delivery: CSII vs MDI.
Fig 2. Effect of pump therapy compared…
Fig 2. Effect of pump therapy compared to multiple daily injections for microvascular complications.
Multivariable analysis (GEE), after inclusion of HbA1c and other confounders: significant reduction for retinopathy after allowing for HbA1c, age and duration; and significant reduction for peripheral nerve abnormalities after allowing for HbA1c, male gender and height SDS.

References

    1. Leonard MJ, Reeves GD. Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med 2001;19: 2293–300.
    1. Davies AG, Baum JD. A decade of insulin infusion pumps. Arch Dis Child 1988;63: 329–32.
    1. Mecklenburg RS, Benson JW Jr, Becker NM, Brazel PL, Fredlund PN, Metz RJ, et al. Clinical use of the insulin infusion pump in 100 patients with type I diabetes. N Engl J Med. 1982;307:513–8.
    1. Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008;51: 941–51. 10.1007/s00125-008-0974-3
    1. Hoogma RP, Hammond PJ, Gomis R, Kerr D, Bruttomesso D, Bouter KP, et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med. 2006;23: 141–7.
    1. Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol. 2010;47S: 77–81.
    1. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care. 2003;26: 1079–87.
    1. Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157: 336–47.
    1. Johnson SR, Cooper MN, Jones TW, Davis EA. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia. 2013;56: 2392–400. 10.1007/s00125-013-3007-9
    1. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care. 2003;26: 1142–6.
    1. Steineck I, Cederholm J, Eliasson B, Rawshani A, Eeg-Olofsson K, Svensson AM, et al. Insulin pump therapy, multiple daily injections and cardiovacular mortality in 18 168 people with type 1 diaebtes: observational study. BMJ. 2015:h3234 10.1136/bmj.h3234
    1. Wheeler BJ, Donaghue KC, Heels K, Ambler GR. Family perceptions of insulin pump adverse events in children and adolescents. Diabetes Technol Ther. 2014;16: 204–7. 10.1089/dia.2013.0315
    1. Wheeler BJ, Heels K, Donaghue KC, Reith DM, Ambler GR. Insulin pump-associated adverse events in children and adolescents—a prospective study. Diabetes Technol Ther. 2014;16: 558–62. 10.1089/dia.2013.0388
    1. Downie E, Craig ME, Hing S, Cusumano J, Chan AKF, Donaghue KC. Continued Reduction in the Prevalence of Retinopathy in Adolescents With Type 1 Diabetes Role of insulin therapy and glycemic control. Diabetes Care 2011;34: 2368–73. 10.2337/dc11-0102
    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329: 977–86.
    1. Mohsin F, Craig ME, Cusumano J, Chan AK, Hing S, Lee JW, et al. Discordant trends in microvascular complications in adolescents with type 1 diabetes from 1990 to 2002. Diabetes Care. 2005;28: 1974–80.
    1. Klein R, Klein BE, Moss SE. The Wisconsin epidemiologic study of diabetic retinopathy: an update. Aust N Z J Ophthalmol. 1990;18: 19–22.
    1. Cho YH, Craig ME, Davis EA, Cotterill AM, Couper JJ, Cameron FJ, et al. Cardiac Autonomic Dysfunction Is Associated With High-Risk Albumin-to-Creatinine Ratio in Young Adolescents With Type 1 Diabetes in AdDIT (Adolescent Type 1 Diabetes Cardio-Renal Interventional Trial). Diabetes Care 2015;38: 676–681. 10.2337/dc14-1848
    1. Cho YH, Craig ME, Srinivasan S, Benitez-Aguirre P, Mitchell P, Jopling T, et al. Heart rate variability in pubertal girls with type 1 diabetes: its relationship with glycaemic control, insulin resistance and hyperandrogenism. Clin Endocrinol. 2014;80: 818–24.
    1. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11. 2002: 1–190.
    1. Task Force on Blood Pressure Control in Children. Report of the Second Task Force on Blood Pressure Control in Children-1987. Pediatrics 1987;79: 1–25.
    1. Australian Bureau of Statistics. SEIFA: socio-economic indexes for areas [Internet], 2006. Available:
    1. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia. 2003;46S: M9–16.
    1. Hirsch IB. Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does! Diabetes Care 2015;38: 1610–1614. 10.2337/dc14-2898
    1. Ceriello A, Ihnat MA. 'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting. Diabet Med. 2010;27: 862–7. 10.1111/j.1464-5491.2010.02967.x
    1. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44: 968–83.
    1. Bragd J, Adamson U, Backlund LB, Lins PE, Moberg E, Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab. 2008;34: 612–6. 10.1016/j.diabet.2008.04.005

Source: PubMed

3
Abonnieren